How Targeted Cancer Drugs Disrupt the Cell Cycle
PLOS: DNA Science
JUNE 22, 2023
Cancer cells make too much survivin, with levels increasing as the disease spreads and becomes more aggressive. It delayed disease progression and more than doubled survival time, adding 17 months. After passing safety tests, Gleevec worked so well that it set a new record for drug approval—10 weeks, on May 10, 2001.
52 
Let's personalize your content